Abstract
Background and Objectives In Machado-Joseph disease or spinocerebellar ataxia type 3 (MJD/SCA3), ataxin-3 accumulates as neuronal nuclear inclusions in specific regions of the brain such as the substantia nigra and the dentate cerebellar nucleus. Ataxin-3 aggregation is strongly inhibited by dopamine, a neurotransmitter whose brain levels can be increased through the use of medication containing levodopa/carbidopa (LA/CA). Here we perform a retrospective study to determine whether exposition to LA/CA is associated with a decreased progression of MJD/SCA3.
Methods We assessed the natural history of individuals with MJD/SCA3 and also SCA1, 2, 6, 7, 8, and 10 enrolled by the Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA). Our initial analysis focused on individuals with all spinocerebellar ataxias (SCAs) whose ataxia progression was assessed by the Scale for the Assessment and Rating of Ataxia (SARA) between 2010 and 2023. To account for important covariates affecting the time evolution of SARA scores, our study was then limited to MJD/SCA3 cases with genetic and age information available. A linear mixed model was used to determine the effects of LA/CA and other anti-parkinsonian drugs at 6 and 13 years of MJD/SCA3 progression.
Results Among the group of 716 individuals with SCAs with monitored SARA scores, 58 (8.1%) had taken LA/CA formulations, whereas 26 (3.6%) had taken other anti-parkinsonian drugs, mainly dopamine receptor agonists. A non-parametric analysis suggested a positive effect of LA/CA on the probability of major disease decline during the initial 6 years of patient monitoring. A multivariate analysis of 262 MJD/SCA3 cases (of which 30 were taken LA/CA) showed statistically significant effects in favor of LA/CA exposition: after adjusting for age and number of CAG repeats in the expanded allele, the yearly SARA response demonstrated a positive effect at 6 years (linear mixed model coefficient β = −0.651 [95% confidence interval −1.141 to −0.161], P = 0.009) and 13 years (β = −0.274 [−0.547 to −0.002], P = 0.048).
Conclusions The use of LA/CA to treat non-cerebellar symptoms had a beneficial effect on the SARA score progression in MJD/SCA3. This observation supports the hypothesis that restoring the dopamine levels in the brains of MJD/SCA3 patients might slow down disease progression. Our findings warrant further investigation on whether individuals with MJD/SCA3, even in the absence of Parkinsonian symptoms should also be treated with LA/CA and at what doses.
Competing Interest Statement
The authors declare the following competing interests: ZS, SMR and PMM are co-inventors in provisional patent applications for the use of low-dose levodopa formulations for the treatment of neurodegenerative disorders.
Funding Statement
This work was funded by National Funds through FCT - Fundacao para a Ciencia e a Tecnologia, I.P., under the project UIDB/04293/2020 and PTDC/QUICOL/2444/2021. PMM is supported by FCT CEECIND/03750/2017/CP1386/CT0014 (https://doi.org/10.54499/CEECIND/03750/2017/CP1386/CT0014). MR is supported by FCT CEECIND/03018/2018/CP1556/CT0009 (https://doi.org/10.54499/CEECIND/03018/2018/CP1556/CT0009).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The uniform study protocol was approved by local institutional review boards, and written informed consent was obtained from each participant. This study does not require additional ethical approval beyond the approvals given for inclusion in the historical cohorts, including informed consent obtained from each participant.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵7 Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA). Detailed composition of the consortium in the acknowledgements section.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
